Developer docs
API playgroundTry for free, no card

Search company profiles

AbClon

Full company profile

uuid0002sn3

Namestring
AbClon
Legal namestring
앱클론 주식회사
Websiteurl
abclon.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

AbClon (앱클론 주식회사) is a Seoul-headquartered, KOSDAQ-listed (ticker A174900) biopharmaceutical company founded in 2010 as a Korea-Sweden joint venture, specializing in antibody-based therapeutics and CAR-T cell therapies. The company operates three proprietary technology platforms: NEST (Novel Epitope Screening Technology) for discovering antibodies targeting novel epitopes, AffiMab for bispecific antibody development combining monoclonal antibodies with Affibody molecules, and zCAR-T (switchable CAR-T) for controllable T-cell activity in solid tumors. Its clinical pipeline includes six programs: AT101/nespe-cel (CD19 CAR-T for relapsed/refractory B-cell lymphoma in Phase 2), AT501 (zCAR-T for HER2-positive solid tumors), AC101/HLX22/dulpatatug (HER2 antibody for first-line gastric cancer in global Phase 3 with partner Henlius), AM201 (IL-6/TNF-α bispecific for autoimmune diseases), AM105 (EGFR×CD137 bispecific), and AM109 (PSMA×CD137 for prostate cancer).

AbClon employs approximately 51-100 people with about 80% in R&D, operates a cGMP manufacturing facility at its Seoul headquarters for CAR-T production, and holds over 80 patents across major jurisdictions. The company serves hematologic and solid tumor patients (relapsed/refractory B-cell lymphoma, HER2-positive gastric and breast cancer, ovarian, prostate, colorectal cancers) as well as autoimmune disease patients (rheumatoid arthritis).

AbClon's business model is structured as a licensing and royalty platform rather than direct commercialization. The company discovers and develops novel therapeutics internally, then out-licenses to larger pharmaceutical partners for global development and commercialization in exchange for upfront payments, development milestones, and ongoing royalties on commercial sales. Its core economic relationship is with Shanghai Henlius Biotech for HLX22/AC101, with Alligator Bioscience entitled to 35% of sublicense revenue. Korea distribution is handled by Chong Kun Dang (also a 7.33% strategic shareholder), and Turkey/Europe expansion is enabled via TCT Health Technology. Revenue is supplemented by government grants (KDDF) and national drug development project funding. As of end-2025, the company held approximately 450 billion KRW in liquid assets and reported revenue exceeding 300 billion KRW for 2025, primarily driven by licensing milestones.

Short descriptiontext

AbClon is a Seoul-based, KOSDAQ-listed biopharmaceutical company developing antibody therapeutics and CAR-T cell therapies through proprietary NEST, AffiMab, and zCAR-T platforms, licensing pipeline assets to partners like Henlius for global development while retaining milestone and royalty economics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics development, CAR-T cell therapy, bispecific antibody platform, oncology drug development, biopharmaceutical licensing
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Antibody Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing and Royalty Revenue
TypeLicensing Royalties
Description

AbClon discovers and develops novel therapeutics, then licenses technology to larger pharmaceutical partners (e.g., Henlius for HLX22/AC101). Revenue is generated through upfront payments, development milestones, and ongoing royalties on commercial sales. Alligator Bioscience receives 35% of AbClon's sublicense revenue from the Henlius agreement.

abclon.com
2Government Grants and R&D Support
TypeProfessional Services
Description

AbClon receives support from government organizations including KDDF (Korea Drug Development Fund) and participates in national drug development projects for CAR-T and other pipeline programs.

abclon.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1NEST Platform
Description

Novel Epitope Screening Technology platform for developing innovative antibody therapeutics targeting new epitopes on disease proteins

abclon.com
+4 more records
Core offering1 text field

AbClon is a clinical-stage biopharmaceutical company that discovers and develops novel antibody therapeutics and CAR-T cell therapies for cancer and autoimmune diseases. The company leverages proprietary technology platforms (NEST, AffiMab, CAR-T, mRMAb) to identify differentiated antibody candidates against novel epitopes, then licenses these candidates to larger pharmaceutical partners for global clinical development and commercialization in exchange for upfront payments, development milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AT101 Phase 2 interim: 94% ORR and 68% CR in relapsed/refractory B-cell lymphoma patients
+3 more records
Product overview1 text field

AbClon is a biopharmaceutical company developing innovative antibody-based therapeutics and CAR-T cell therapies through three proprietary technology platforms: NEST (Novel Epitope Screening Technology) for antibody discovery, AffiMab for bispecific antibody development, and CAR-T platform for gene-modified cell therapy. The company's pipeline includes six clinical-stage products: AT101 (nespe-cel), a CD19-targeting CAR-T for blood cancers; AT501 (zCAR-T), a switchable CAR-T for HER2-positive solid tumors; AC101 (dulpatatug/HLX22), a HER2-targeting antibody licensed to Henlius for gastric cancer in global Phase 3; AM201 for autoimmune diseases; and AM105 and AM109, bispecific antibodies for solid tumors and prostate cancer respectively. AbClon operates cGMP manufacturing facilities and maintains global partnerships including licensing AC101 to Shanghai Henlius Biotech.

Product and service9 records
1AT101 (Nespe-cel)
CategoryCAR-T Cell Therapy
Description

CD19-targeting CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and B-cell non-Hodgkin lymphoma. Uses AbClon's proprietary humanized h1218 antibody with faster on/off rates and reduced trogocytosis compared to FMC63-based competitor antibodies. WHO INN: 'nespe-cel'. Phase 2 clinical trials ongoing in Korea.

2AT501 (zCAR-T)
CategoryCAR-T Cell Therapy
Description

Switchable CAR-T therapy for HER2-positive solid tumors (ovarian cancer and other solid tumors). Built on the zCAR-T platform using Affibody and switch molecules to enable precise on/off control and dose modulation of T-cell activity, minimizing fatal side effects (CRS, ICANS) while maintaining efficacy.

3AC101 (Dulpatatug / HLX22)
CategoryMonoclonal Antibody Therapeutics
Description

HER2-targeting antibody for first-line treatment of HER2-positive gastric/gastroesophageal junction cancer and HER2-positive/low breast cancer. Licensed to Shanghai Henlius Biotech (HLX22 development code). Targets HER2 Domain IV with a different epitope than trastuzumab, enabling synergistic dual blockade. Global Phase 3 (HLX22-GC-301) ongoing with 550 patients across Korea, US, Europe, China, Japan, Latin America, and Australia. Phase 2 showed HR 0.20 (80% reduction in disease progression risk) vs standard of care.

4AM201
CategoryBispecific Antibody Therapeutics
Description

Bispecific antibody for autoimmune diseases (rheumatoid arthritis) that simultaneously targets IL-6 and TNF-α. Developed on the AffiMab platform to overcome limitations of single-target biologics. US patent registered May 2026.

5AM105
CategoryBispecific Antibody Therapeutics
Description

Bispecific immunotherapy antibody simultaneously targeting EGFR on cancer cells and CD137 (4-1BB) on immune cells. Developed on the AffiMab platform for solid tumor treatment.

6AM109
CategoryBispecific Antibody Therapeutics
Description

Bispecific T-cell engager targeting PSMA on prostate cancer cells and CD137 (4-1BB) on T-cells. Developed on the AffiMab platform for treatment-refractory prostate cancer.

7NEST Platform (Novel Epitope Screening Technology)
CategoryAntibody Discovery Platform
Description

Proprietary antibody discovery platform that identifies antibodies binding to novel epitopes on disease proteins, enabling therapeutic effects differentiated from existing antibody treatments. Licensed and utilized for partner antibody discovery programs.

8AffiMab Platform
CategoryBispecific Antibody Platform
Description

Bispecific antibody development platform combining monoclonal antibodies with Affibody molecules to simultaneously target two disease protein epitopes, maximizing therapeutic effects in refractory diseases. Licensed and co-developed with partners including Chong Kun Dang.

9CAR-T Platform (zCAR-T Switchable)
CategoryCell Therapy Platform
Description

Personalized anti-cancer gene-modified cell therapy platform. Extracts patient immune cells, genetically modifies them to selectively attack cancer cells, then reinfuses. Includes proprietary switchable zCAR-T technology allowing on/off control and dose modulation to address solid tumor challenges. Operated with cGMP manufacturing facility in Seoul.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Chong Kun Dang (종근당)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

Strategic partnership for co-development of bispecific antibody therapeutics using AffiMab platform. Chong Kun Dang acquired 7.33% stake (2nd largest shareholder) in 2025 through 122 billion KRW equity investment. Holds exclusive sales priority rights for AT101 in Korea.

abclon.com
2TCT Health Technology (Turkey)
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-02-01
Description

Technology transfer agreement for AT101/Nespe-cel commercialization in Turkey. TCT handles clinical development and commercialization costs while AbClon receives contract fees and royalties on net sales.

abclon.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

Joint research and development agreement for gastric cancer CAR-T therapy.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2020-01-01
Description

Technology transfer of HER2 antibody for CAR-NK cell therapy development targeting solid tumors. GC LabCell is developing AB-201 incorporating AbClon's HER2 antibody.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Joint development partnership for innovative CAR-T therapy research. Collaboration has produced joint publications in Nature Immunology on BTLA knockout CAR-T technology.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-05-01
Description

Joint development partnership for immune-oncology bispecific antibody drugs using AbClon's technology platforms.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2018-02-01
Description

Technology collaboration utilizing Affibody molecules in AbClon's AffiMab bispecific antibody platform and zCAR-T switch technology.

8Shanghai Henlius Biotech (Henlius)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-10-01
Description

AbClon licensed AC101 to Henlius for global development and commercialization. Henlius is developing HLX22 (AC101) for HER2-positive gastric cancer and breast cancer. AbClon receives milestone payments and royalties on sales. Henlius has advanced HLX22 to global Phase 3 trials with ODD from FDA and EC.

abclon.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-05-01
Description

Buy-out agreement for jointly developed antibody treatments. Alligator is entitled to receive 35% of AbClon's revenue from sublicensing to Henlius.

10Seoul Asan Medical Center
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2015-05-01
Description

Clinical trial site for AT101 CAR-T therapy. First patient dosing for Phase 1 initiated at Seoul Asan Medical Center.

abclon.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2010-06-01
Description

Founding collaboration with Swedish researchers including Professor Matthias Uhlén. Foundation of AbClon's antibody development expertise and NEST platform technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Adagene is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics using proprietary discovery platforms (POWER platform for novel epitope targeting). Directly comparable to AbClon's NEST platform for novel antibody discovery.

TypeDirect peer
Description

Zymeworks develops bispecific antibodies and antibody-drug conjugates for cancer treatment, with platforms including Azymetric and ZymeLink. Comparable to AbClon's AffiMab bispecific platform and cotinine-based ADC conjugation technology.

TypeDirect peer
Description

Allogene Therapeutics develops allogeneic CAR-T cell therapies for blood cancers and solid tumors. Directly comparable to AbClon's autologous CAR-T and zCAR-T platforms, both targeting hematologic and solid tumor indications with novel cell engineering approaches.

TypeDirect peer
Description

MacroGenics develops bispecific antibodies and antibody-based therapeutics for cancer and autoimmune diseases, including margetuximab (HER2-targeted) and enoblituzumab. Directly comparable to AbClon's HER2 antibody HLX22 and bispecific pipeline including AM201.

5Shanghai Henlius Biotech
TypeRegional player
Description

Shanghai Henlius is a Chinese biopharmaceutical company focused on oncology biologics and biosimilars, which licensed AbClon's HLX22/AC101 antibody for global development. Comparable as a regional biologics developer with overlapping HER2 antibody expertise but primarily serving the China market.

TypeBroad incumbent
Description

GenScript ProBio is a global biologics CDMO offering cell therapy, gene therapy, and antibody drug development and manufacturing services. Comparable as a broader industry incumbent providing contract development services across biologics and cell therapy modalities relevant to AbClon's platform technologies.

TypeDirect peer
Description

Legend Biotech is a clinical-stage biopharmaceutical company developing CAR-T cell therapies, most notably cilta-cel for multiple myeloma in partnership with Janssen. Comparable to AbClon's CAR-T franchise in modality, target indications, and licensing-based commercialization model.

TypeRegional player
Description

Yuhan Corporation is a major Korean pharmaceutical company with biosimilar and novel biologics development programs. As an AbClon partner (joint bispecific antibody development since 2018), Yuhan is a regional comparable in Korean biotech innovation with broader commercial scale.

TypeDirect peer
Description

Cellectis is a clinical-stage biopharmaceutical company developing allogeneic CAR-T therapies using proprietary TALEN gene editing. Comparable to AbClon's CAR-T and zCAR-T platforms in cell therapy modality and novel engineering approaches.

TypeBroad incumbent
Description

WuXi Biologics is a leading global biologics CDMO providing end-to-end development and manufacturing services for monoclonal antibodies and bispecifics. Comparable as a broader biologics industry incumbent providing infrastructure that supports the type of antibody development AbClon performs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AbClon

Biopharmaceutical Antibody Therapeuticsabclon.com

AbClon is a Seoul-based, KOSDAQ-listed biopharmaceutical company developing antibody therapeutics and CAR-T cell therapies through proprietary NEST, AffiMab, and zCAR-T platforms, licensing pipeline assets to partners like Henlius for global development while retaining milestone and royalty economics.

What AbClon does

AbClon (앱클론 주식회사) is a Seoul-headquartered, KOSDAQ-listed (ticker A174900) biopharmaceutical company founded in 2010 as a Korea-Sweden joint venture, specializing in antibody-based therapeutics and CAR-T cell therapies. The company operates three proprietary technology platforms: NEST (Novel Epitope Screening Technology) for discovering antibodies targeting novel epitopes, AffiMab for bispecific antibody development combining monoclonal antibodies with Affibody molecules, and zCAR-T (switchable CAR-T) for controllable T-cell activity in solid tumors. Its clinical pipeline includes six programs: AT101/nespe-cel (CD19 CAR-T for relapsed/refractory B-cell lymphoma in Phase 2), AT501 (zCAR-T for HER2-positive solid tumors), AC101/HLX22/dulpatatug (HER2 antibody for first-line gastric cancer in global Phase 3 with partner Henlius), AM201 (IL-6/TNF-α bispecific for autoimmune diseases), AM105 (EGFR×CD137 bispecific), and AM109 (PSMA×CD137 for prostate cancer).

AbClon employs approximately 51-100 people with about 80% in R&D, operates a cGMP manufacturing facility at its Seoul headquarters for CAR-T production, and holds over 80 patents across major jurisdictions. The company serves hematologic and solid tumor patients (relapsed/refractory B-cell lymphoma, HER2-positive gastric and breast cancer, ovarian, prostate, colorectal cancers) as well as autoimmune disease patients (rheumatoid arthritis).

AbClon's business model is structured as a licensing and royalty platform rather than direct commercialization. The company discovers and develops novel therapeutics internally, then out-licenses to larger pharmaceutical partners for global development and commercialization in exchange for upfront payments, development milestones, and ongoing royalties on commercial sales. Its core economic relationship is with Shanghai Henlius Biotech for HLX22/AC101, with Alligator Bioscience entitled to 35% of sublicense revenue. Korea distribution is handled by Chong Kun Dang (also a 7.33% strategic shareholder), and Turkey/Europe expansion is enabled via TCT Health Technology. Revenue is supplemented by government grants (KDDF) and national drug development project funding. As of end-2025, the company held approximately 450 billion KRW in liquid assets and reported revenue exceeding 300 billion KRW for 2025, primarily driven by licensing milestones.

AbClon firmographics

Firmographics
Name
AbClon
Legal name
앱클론 주식회사
Website
https://abclon.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
AbClon is a Seoul-based, KOSDAQ-listed biopharmaceutical company developing antibody therapeutics and CAR-T cell therapies through proprietary NEST, AffiMab, and zCAR-T platforms, licensing pipeline assets to partners like Henlius for global development while retaining milestone and royalty economics.
Ownership category
akta.pro rank

AbClon industry classification

Industry
Product category
Biopharmaceutical Antibody Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Antibody therapeutics development
  • CAR-T cell therapy
  • Bispecific antibody platform
  • Oncology drug development
  • Biopharmaceutical licensing

Where AbClon is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

AbClon business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing and Royalty Revenue: AbClon discovers and develops novel therapeutics, then licenses technology to larger pharmaceutical partners (e.g., Henlius for HLX22/AC101). Revenue is generated through upfront payments, development milestones, and ongoing royalties on commercial sales. Alligator Bioscience receives 35% of AbClon's sublicense revenue from the Henlius agreement.
  2. Government Grants and R&D Support: AbClon receives support from government organizations including KDDF (Korea Drug Development Fund) and participates in national drug development projects for CAR-T and other pipeline programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

AbClon product offering

Product offering

Core offering

AbClon is a clinical-stage biopharmaceutical company that discovers and develops novel antibody therapeutics and CAR-T cell therapies for cancer and autoimmune diseases. The company leverages proprietary technology platforms (NEST, AffiMab, CAR-T, mRMAb) to identify differentiated antibody candidates against novel epitopes, then licenses these candidates to larger pharmaceutical partners for global clinical development and commercialization in exchange for upfront payments, development milestones, and royalties.

Product overview

AbClon is a biopharmaceutical company developing innovative antibody-based therapeutics and CAR-T cell therapies through three proprietary technology platforms: NEST (Novel Epitope Screening Technology) for antibody discovery, AffiMab for bispecific antibody development, and CAR-T platform for gene-modified cell therapy. The company's pipeline includes six clinical-stage products: AT101 (nespe-cel), a CD19-targeting CAR-T for blood cancers; AT501 (zCAR-T), a switchable CAR-T for HER2-positive solid tumors; AC101 (dulpatatug/HLX22), a HER2-targeting antibody licensed to Henlius for gastric cancer in global Phase 3; AM201 for autoimmune diseases; and AM105 and AM109, bispecific antibodies for solid tumors and prostate cancer respectively. AbClon operates cGMP manufacturing facilities and maintains global partnerships including licensing AC101 to Shanghai Henlius Biotech.

Differentiator

Problem solved

Functional benefit

Brands

  • NEST Platform: Novel Epitope Screening Technology platform for developing innovative antibody therapeutics targeting new epitopes on disease proteins
  • AffiMab Platform
  • zCAR-T Platform
  • Nespe-cel (AT101)
  • mRMAb Platform

Products and services

  • AT101 (Nespe-cel) CD19-targeting CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and B-cell non-Hodgkin lymphoma. Uses AbClon's proprietary humanized h1218 antibody with faster on/off rates and reduced trogocytosis compared to FMC63-based competitor antibodies. WHO INN: 'nespe-cel'. Phase 2 clinical trials ongoing in Korea.
  • AT501 (zCAR-T) Switchable CAR-T therapy for HER2-positive solid tumors (ovarian cancer and other solid tumors). Built on the zCAR-T platform using Affibody and switch molecules to enable precise on/off control and dose modulation of T-cell activity, minimizing fatal side effects (CRS, ICANS) while maintaining efficacy.
  • AC101 (Dulpatatug / HLX22) HER2-targeting antibody for first-line treatment of HER2-positive gastric/gastroesophageal junction cancer and HER2-positive/low breast cancer. Licensed to Shanghai Henlius Biotech (HLX22 development code). Targets HER2 Domain IV with a different epitope than trastuzumab, enabling synergistic dual blockade. Global Phase 3 (HLX22-GC-301) ongoing with 550 patients across Korea, US, Europe, China, Japan, Latin America, and Australia. Phase 2 showed HR 0.20 (80% reduction in disease progression risk) vs standard of care.
  • AM201 Bispecific antibody for autoimmune diseases (rheumatoid arthritis) that simultaneously targets IL-6 and TNF-α. Developed on the AffiMab platform to overcome limitations of single-target biologics. US patent registered May 2026.
  • AM105 Bispecific immunotherapy antibody simultaneously targeting EGFR on cancer cells and CD137 (4-1BB) on immune cells. Developed on the AffiMab platform for solid tumor treatment.
  • AM109 Bispecific T-cell engager targeting PSMA on prostate cancer cells and CD137 (4-1BB) on T-cells. Developed on the AffiMab platform for treatment-refractory prostate cancer.
  • NEST Platform (Novel Epitope Screening Technology) Proprietary antibody discovery platform that identifies antibodies binding to novel epitopes on disease proteins, enabling therapeutic effects differentiated from existing antibody treatments. Licensed and utilized for partner antibody discovery programs.
  • AffiMab Platform Bispecific antibody development platform combining monoclonal antibodies with Affibody molecules to simultaneously target two disease protein epitopes, maximizing therapeutic effects in refractory diseases. Licensed and co-developed with partners including Chong Kun Dang.
  • CAR-T Platform (zCAR-T Switchable) Personalized anti-cancer gene-modified cell therapy platform. Extracts patient immune cells, genetically modifies them to selectively attack cancer cells, then reinfuses. Includes proprietary switchable zCAR-T technology allowing on/off control and dose modulation to address solid tumor challenges. Operated with cGMP manufacturing facility in Seoul.

Quantifiable outcome

  • AT101 Phase 2 interim: 94% ORR and 68% CR in relapsed/refractory B-cell lymphoma patients
  • +3 more outcomes

Companies that use AbClon

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

AbClon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AbClon partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and major.

  • Chong Kun Dang (종근당)coreStrategic or Co-development Partner · 1 March 2025Strategic partnership for co-development of bispecific antibody therapeutics using AffiMab platform. Chong Kun Dang acquired 7.33% stake (2nd largest shareholder) in 2025 through 122 billion KRW equity investment. Holds exclusive sales priority rights for AT101 in Korea.
  • TCT Health Technology (Turkey)majorTechnology or Integration · 1 February 2025Technology transfer agreement for AT101/Nespe-cel commercialization in Turkey. TCT handles clinical development and commercialization costs while AbClon receives contract fees and royalties on net sales.
  • National Cancer Center KoreamajorStrategic or Co-development Partner · 1 March 2022Joint research and development agreement for gastric cancer CAR-T therapy.
  • GC Green Cross LabCell (GC녹십자랩셀)majorTechnology or Integration · 1 January 2020Technology transfer of HER2 antibody for CAR-NK cell therapy development targeting solid tumors. GC LabCell is developing AB-201 incorporating AbClon's HER2 antibody.
  • University of Pennsylvania (Penn)majorStrategic or Co-development Partner · 1 January 2020Joint development partnership for innovative CAR-T therapy research. Collaboration has produced joint publications in Nature Immunology on BTLA knockout CAR-T technology.
  • Yuhan Corporation (유한양행)majorStrategic or Co-development Partner · 1 May 2018Joint development partnership for immune-oncology bispecific antibody drugs using AbClon's technology platforms.
  • Affibody ABmajorTechnology or Integration · 1 February 2018Technology collaboration utilizing Affibody molecules in AbClon's AffiMab bispecific antibody platform and zCAR-T switch technology.
  • Shanghai Henlius Biotech (Henlius)coreTechnology or Integration · 1 October 2016AbClon licensed AC101 to Henlius for global development and commercialization. Henlius is developing HLX22 (AC101) for HER2-positive gastric cancer and breast cancer. AbClon receives milestone payments and royalties on sales. Henlius has advanced HLX22 to global Phase 3 trials with ODD from FDA and EC.
  • Alligator Bioscience ABmajorStrategic or Co-development Partner · 1 May 2016Buy-out agreement for jointly developed antibody treatments. Alligator is entitled to receive 35% of AbClon's revenue from sublicensing to Henlius.
  • Seoul Asan Medical CentermajorStrategic or Co-development Partner · 1 May 2015Clinical trial site for AT101 CAR-T therapy. First patient dosing for Phase 1 initiated at Seoul Asan Medical Center.
  • KTH Royal Institute of Technology (스웨덴 왕립과학원)coreTechnology or Integration · 1 June 2010Founding collaboration with Swedish researchers including Professor Matthias Uhlén. Foundation of AbClon's antibody development expertise and NEST platform technology.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

AbClon competitors and assessment

Company assessment

Direct peers

  • Adagene: Adagene is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics using proprietary discovery platforms (POWER platform for novel epitope targeting). Directly comparable to AbClon's NEST platform for novel antibody discovery.
  • Zymeworks: Zymeworks develops bispecific antibodies and antibody-drug conjugates for cancer treatment, with platforms including Azymetric and ZymeLink. Comparable to AbClon's AffiMab bispecific platform and cotinine-based ADC conjugation technology.
  • Allogene Therapeutics: Allogene Therapeutics develops allogeneic CAR-T cell therapies for blood cancers and solid tumors. Directly comparable to AbClon's autologous CAR-T and zCAR-T platforms, both targeting hematologic and solid tumor indications with novel cell engineering approaches.
  • MacroGenics: MacroGenics develops bispecific antibodies and antibody-based therapeutics for cancer and autoimmune diseases, including margetuximab (HER2-targeted) and enoblituzumab. Directly comparable to AbClon's HER2 antibody HLX22 and bispecific pipeline including AM201.
  • Legend Biotech: Legend Biotech is a clinical-stage biopharmaceutical company developing CAR-T cell therapies, most notably cilta-cel for multiple myeloma in partnership with Janssen. Comparable to AbClon's CAR-T franchise in modality, target indications, and licensing-based commercialization model.
  • Cellectis: Cellectis is a clinical-stage biopharmaceutical company developing allogeneic CAR-T therapies using proprietary TALEN gene editing. Comparable to AbClon's CAR-T and zCAR-T platforms in cell therapy modality and novel engineering approaches.

Regional players

  • Shanghai Henlius Biotech: Shanghai Henlius is a Chinese biopharmaceutical company focused on oncology biologics and biosimilars, which licensed AbClon's HLX22/AC101 antibody for global development. Comparable as a regional biologics developer with overlapping HER2 antibody expertise but primarily serving the China market.
  • Yuhan Corporation: Yuhan Corporation is a major Korean pharmaceutical company with biosimilar and novel biologics development programs. As an AbClon partner (joint bispecific antibody development since 2018), Yuhan is a regional comparable in Korean biotech innovation with broader commercial scale.

Broad incumbents

  • GenScript ProBio: GenScript ProBio is a global biologics CDMO offering cell therapy, gene therapy, and antibody drug development and manufacturing services. Comparable as a broader industry incumbent providing contract development services across biologics and cell therapy modalities relevant to AbClon's platform technologies.
  • WuXi Biologics: WuXi Biologics is a leading global biologics CDMO providing end-to-end development and manufacturing services for monoclonal antibodies and bispecifics. Comparable as a broader biologics industry incumbent providing infrastructure that supports the type of antibody development AbClon performs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AbClon compliance and trust

Trust signal

Compliance11 records

AbClon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AbClon leadership team

Management profile

Number of profiles

Profiles1 record

AbClon funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AbClon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AbClon

What does AbClon do?

AbClon is a clinical-stage biopharmaceutical company that discovers and develops novel antibody therapeutics and CAR-T cell therapies for cancer and autoimmune diseases. The company leverages proprietary technology platforms (NEST, AffiMab, CAR-T, mRMAb) to identify differentiated antibody candidates against novel epitopes, then licenses these candidates to larger pharmaceutical partners for global clinical development and commercialization in exchange for upfront payments, development milestones, and royalties.

Is AbClon a public or private company?

AbClon is a public company. It is classified as public and is currently operating.

When was AbClon founded?

AbClon was founded in 2010. It employs 11 to 50 people.

Where is AbClon based?

AbClon is headquartered in Seoul, South Korea, in the Asia region.

How does AbClon make money?

Two revenue lines are on record. Technology Licensing and Royalty Revenue is the primary driver. The others are government Grants and R&D Support.

Who are AbClon's main competitors?

Direct peers on record are Adagene, Zymeworks, Allogene Therapeutics, MacroGenics, Legend Biotech and Cellectis. Regional players are Shanghai Henlius Biotech and Yuhan Corporation. Broad incumbents are GenScript ProBio and WuXi Biologics.

Does AbClon have an API?

No public API is recorded for AbClon.

What industry is AbClon in?

AbClon's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAbClon Signs KRW 1 Billion Settlement Agreement With YuhanAbClon signed an amended settlement agreement with Yuhan on Oct. 30, 2026, concluding their TIGIT-targeted antibody drug development collaboration. The settlement totals 1 billion won, at least 10% of the previous fiscal year's revenue, and transfers all research rights to Yuhan.The future of tradingAbClon Extends Supply Contract End Date to Dec. 31, 2026AbClon corrected its supply contract end date to Dec. 31, 2026, from Oct. 31, 2026, citing settlement and administrative procedures. The KRW 355.76 million contract covers reagents and laboratory equipment for the National Institute of Food and Drug Safety Evaluation and represents 7.5% of annual revenue.NaverAbClon Secures Japanese Patent for Revolutionary zCAR-T Technology: What This Means for Cancer TreatmentAbClon secured a Japanese patent for its zCAR-T CAR-T therapy platform, covering antibody and CAR receptor technology. The platform uses a switch molecule to modulate T-cell activity, aiming to reduce side effects and target multiple cancer types. The company is developing AT501 for HER2-positive solid tumors and plans to expand into multi-target therapies.AInvestHER2+ Gastric Cancer Therapies: A Race to Asia-Pacific Dominance Through ADCs and Immunotherapy InnovationAstraZeneca, Merck, and Roche are racing to capture the Asia-Pacific HER2+ gastric cancer market, projected to exceed $700 million by 2024. AstraZeneca's ENHERTU is advancing into first-line trials, while Merck and Roche focus on combination therapies and diagnostics. Regional players like Shanghai Henlius and AbClon pose pricing threats.ChosunbizFDA Eases CAR-T Therapy Regulations, Boosting Global Pharmaceutical CompetitionThe FDA removed REMS requirements for CAR-T therapies, easing regulations and intensifying global competition. The market is projected to grow from 10 trillion won last year to over 15 trillion this year, reaching 256 trillion by 2034. Domestic firms like Curocell and AbClon are seeking overseas expansion opportunities.The Korea HeraldYuhan-AbClon’s COVID-19 antibody therapy revs up for trialsYuhan and AbClon have identified a COVID-19 antibody candidate that blocks ACE2 binding and shows neutralizing effects against S-strain and G-strain mutations. They plan to begin human testing before year-end, with Korea's Ministry of Health assigning a 45 billion won ($37.5 million) budget for clinical trials.